share_log

Looking At Bristol-Myers Squibb's Recent Unusual Options Activity

Looking At Bristol-Myers Squibb's Recent Unusual Options Activity

關注施貴寶近期的期權異動
Benzinga ·  07/02 22:46

Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE:BMY) revealed 8 unusual trades.

金融巨頭在施貴寶上做空。我們對紐交所施貴寶(BMY)期權歷史的分析顯示,有8次飛凡交易。

Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $222,715, and 5 were calls, valued at $303,050.

進一步了解,我們發現37%的交易者看好,而62%的交易者則持看淡態度。我們觀察到的所有交易中,3次是看跌期權,價值爲22.2715萬美元,5次是看漲期權,價值爲30.305萬美元。

Projected Price Targets

預計價格目標

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $39.0 and $49.0 for Bristol-Myers Squibb, spanning the last three months.

經過對成交量和持倉的評估,顯然主要的市場搬運工正在關注施貴寶的價格區間,在過去的三個月中處於39.0至49.0美元之間。

Volume & Open Interest Trends

成交量和未平倉量趨勢

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Bristol-Myers Squibb's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Bristol-Myers Squibb's substantial trades, within a strike price spectrum from $39.0 to $49.0 over the preceding 30 days.

在期權交易中,評估成交量和持倉是一個戰略性的步驟。這些指標揭示了施貴寶期權在特定執行價格上的流動性和投資者興趣。即將公佈的數據將在過去30天內,以39.0至49.0美元的執行價格區間內的看跌和看漲期權的成交量和持倉變化圖表上展現施貴寶實質性交易的波動。

Bristol-Myers Squibb Option Activity Analysis: Last 30 Days

施貴寶期權活動分析:過去30天

Options Call Chart

Largest Options Trades Observed:

觀察到的最大期權交易:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
BMY CALL SWEEP BULLISH 12/20/24 $4.0 $3.9 $4.0 $39.00 $119.6K 57 1
BMY PUT SWEEP BEARISH 12/20/24 $9.3 $9.2 $9.3 $49.00 $105.0K 121 0
BMY PUT SWEEP BEARISH 09/20/24 $5.75 $5.65 $5.75 $46.00 $87.4K 1.8K 0
BMY CALL SWEEP BULLISH 07/19/24 $1.93 $1.12 $1.74 $39.00 $64.1K 445 0
BMY CALL SWEEP BEARISH 07/26/24 $1.44 $1.38 $1.38 $40.00 $46.2K 296 261
標的 看跌/看漲 交易類型 情緒 到期日 賣盤 買盤 價格 執行價格 總交易價格 未平倉合約數量 成交量
BMY 看漲 SWEEP 看好 12/20/24 $4.0 $3.9 $4.0 $39.00 $119.6K 57 1
BMY 看跌 SWEEP 看淡 12/20/24 $9.3 $9.2 $9.3 49.00美元 $105.0K 121 0
BMY 看跌 SWEEP 看淡 09/20/24 $5.75 $5.65 $5.75 $46.00 $87.4K 1.8K 0
BMY 看漲 SWEEP 看好 07/19/24 $1.93 $1.12 $1.74 $39.00 $64.1K 445 0
BMY 看漲 SWEEP 看淡 07/26/24 $1.44 $1.38應翻譯爲1.38美元 $1.38應翻譯爲1.38美元 $40.00 $46.2千 296 261

About Bristol-Myers Squibb

關於施貴寶

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

施貴寶發現、開發和營銷用於心血管疾病、癌症和免疫障礙等多種治療領域的藥品。施貴寶的重點關注點是免疫腫瘤學,該公司是藥品研發領域的領導者。施貴寶近70%的總銷售額來自美國,顯示了該公司對美國市場的更高依賴性,高於其大多數同行。

Following our analysis of the options activities associated with Bristol-Myers Squibb, we pivot to a closer look at the company's own performance.

在對施貴寶期權活動進行分析之後,我們轉而更加關注公司自身的業績情況。

Bristol-Myers Squibb's Current Market Status

施貴寶目前的市場狀態幣

  • With a trading volume of 2,060,715, the price of BMY is down by -1.53%, reaching $40.67.
  • Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
  • Next earnings report is scheduled for 24 days from now.
  • BMY 的交易量爲2,060,715,價格下跌1.53%,達到40.67美元。
  • 目前的RSI值表明該股票目前處於超買和超賣之間的中立狀態。
  • 下一季度的業績將於24天后公佈。

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

期權與僅交易股票相比是一種更具風險的資產,但它們具有更高的利潤潛力。認真的期權交易者通過每日學習,進出交易,跟隨多個指標並密切關注市場來管理這種風險。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論